Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophreniform Disorder Clear all
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional

Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders

NCT04418011
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation, Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation), Repetitive Transcranial Magnetic Stimulation (Sham)
Device
Lead sponsor
Centre for Addiction and Mental Health
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Catonsville, Maryland • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

NCT00287352
View directory record Official record
Conditions
Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions
Olanzapine, Amantadine, Olanzapine and placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam in Early Psychosis

NCT03129360
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 21, 2026, 10:24 AM EDT
Terminated Phase 4 Interventional Results available

Antipsychotic Effects on Brain Function in Schizophrenia

NCT01913327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Aripiprazole, Risperidone, Modafinil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 21, 2026, 10:24 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 21, 2026, 10:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Circuits in Schizophrenia and Smoking

NCT01425684
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
12 Years to 80 Years
Enrollment
837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

An Integrated Program for the Treatment of First Episode of Psychosis

NCT01321177
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder, Psychotic Disorder NOS
Interventions
Integrated Treatment, Community Care
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
33
States / cities
San Fernando, California • Santa Clarita, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 21, 2026, 10:24 AM EDT
Recruiting Not applicable Interventional

iTBS to Enhance Social Cognition in People With Psychosis

NCT06118268
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
Interventions
iTBS (Active), iTBS (Sham)
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional

Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia

NCT00434980
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Family-Directed Cognitive Adaptation Program
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Remote State Representation in Early Psychosis

NCT05538832
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders, Psychotic Disorders, Psychotic Mood Disorders, Psychoses, Affective, Psychosis Nos/Other, Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm, BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 30 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Horyzons: Implementation in Clinical Practice

NCT04673851
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional

A Comparative Study of New Medications for Psychosis in Adolescents

NCT00222495
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions
quetiapine, olanzapine, risperidone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 21, 2026, 10:24 AM EDT
Recruiting Not applicable Interventional

Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

NCT05890183
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive training, Aerobic Exercise Program, Moderated Online Social Therapy (MOST), Chorus Participatory Text Messaging Program, Healthy Living Group (HLG)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

rTMS in First Episode Psychosis

NCT02131129
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
rTMS, Sham Comparator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 21, 2026, 10:24 AM EDT
Recruiting Not applicable Interventional

REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

NCT07006935
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness, Usual Community-Based Mental Health Care
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy

NCT03067311
View directory record Official record
Conditions
Schizophreniform Disorders
Interventions
I-CAT, Treatment as Usual
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Carrboro, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

NCT00595504
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

NCT04013555
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
N-acetylcysteine (NAC), Placebo, Tryptophan
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Minnesota Community-Based Cognitive Training in Early Psychosis

NCT03079024
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions
Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Phase 4 Interventional

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions
Sibutramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
16
States / cities
El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional

Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy

NCT00791440
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Cognitive-Behavior Therapy, Standard Psychiatric Treatment
Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 21, 2026, 10:24 AM EDT
Completed Not applicable Interventional

Integrated Metacognitive Therapy in First Episode Psychosis

NCT02131116
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Integrated Metacognitive Therapy, Treatment as Usual
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 21, 2026, 10:24 AM EDT